Impact of potential multiple drug-drug interactions on the adverse event profile of patients with hepatitis C treated with pangenotypic direct-acting antivirals in Spain
PLWHCV predicted to have multiple DDIs are at high risk of AEs. Moreover, fewer comedication-associated AEs were identified with the PI-free DAA SOF/VEL as compared with GLE/PIB.
Authors
- Marinela Méndez
- Juan Turnés (ORCID: https://orcid.org/0000-0001-8426-6145)
- Antoni Sicras‐Mainar (ORCID: https://orcid.org/0000-0002-8232-293X)
- Ramón Morillo‐Verdugo (ORCID: https://orcid.org/0000-0002-8849-2737)
- Antonio García‐Herola (ORCID: https://orcid.org/0000-0002-6755-4994)
- Cándido Hernández
Institutions
- Gilead Sciences (Spain) (ES)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Gilead Sciences (Australia) (AU)
- Hospital Universitario de Valme (ES)
- Hospital Marina Baixa (ES)
- Complejo Hospitalario de Pontevedra (ES)
Publication Details
- Journal
- Revista Española de Sanidad Penitenciaria
- Published
- 2024-11-05
- DOI
- https://doi.org/10.18176/resp.00095
- Citations
- 5
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 1.85
Funders
- Gilead Sciences